Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauri E Markowitz

Showing results (61-70 of 290) with videos related to

Pageof 29
Sort By:
Vaccine|June 12, 2018
Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United StatesHarrell W Chesson, Elissa Meites, Donatus U Ekwueme, et al.
Sexually Transmitted Diseases|December 25, 2007
Assessing neonatal herpes reporting in the United States, 2000-2005Thu-Ha Dinh, Eileen F Dunne, Lauri E Markowitz, et al.
The Journal of Infectious Diseases|September 2, 2009
Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004Lauri E Markowitz, Maya Sternberg, Eileen F Dunne, et al.
Sexually Transmitted Diseases|January 16, 2007
Contact-tracing outcomes among male syphilis patients in Fulton County, Georgia, 2003Erika Samoff, Emilia H Koumans, Steven Katkowsky, et al.
Human Vaccines & Immunotherapeutics|May 21, 2019
Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United StatesHarrell W Chesson, Elissa Meites, Donatus U Ekwueme, et al.
Annals of Internal Medicine|November 17, 2025
Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United StatesJean-François Laprise, Harrell W Chesson, Lauri E Markowitz, et al.
The Journal of Infectious Diseases|December 26, 2013
Reply to Groner et al and Pei et alLauri E Markowitz, Susan Hariri, Eileen F Dunne, et al.
The Journal of Infectious Diseases|May 29, 2016
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness AnalysisJean-François Laprise, Lauri E Markowitz, Harrell W Chesson, et al.
The Journal of Infectious Diseases|February 28, 2002
Persons with early syphilis identified through blood or plasma donation screening in the United StatesCarolyn Gardella, Anthony A Marfin, Richard H Kahn, et al.
Vaccine|October 30, 2020
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission modelHarrell W Chesson, Elissa Meites, Donatus U Ekwueme, et al.
Pageof 29

Showing results (61-70 of 290) with videos related to

Sort By:
Pageof 29
Vaccine|June 12, 2018
Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United StatesHarrell W Chesson, Elissa Meites, Donatus U Ekwueme, et al.
Sexually Transmitted Diseases|December 25, 2007
Assessing neonatal herpes reporting in the United States, 2000-2005Thu-Ha Dinh, Eileen F Dunne, Lauri E Markowitz, et al.
The Journal of Infectious Diseases|September 2, 2009
Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004Lauri E Markowitz, Maya Sternberg, Eileen F Dunne, et al.
Sexually Transmitted Diseases|January 16, 2007
Contact-tracing outcomes among male syphilis patients in Fulton County, Georgia, 2003Erika Samoff, Emilia H Koumans, Steven Katkowsky, et al.
Human Vaccines & Immunotherapeutics|May 21, 2019
Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United StatesHarrell W Chesson, Elissa Meites, Donatus U Ekwueme, et al.
Annals of Internal Medicine|November 17, 2025
Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United StatesJean-François Laprise, Harrell W Chesson, Lauri E Markowitz, et al.
The Journal of Infectious Diseases|December 26, 2013
Reply to Groner et al and Pei et alLauri E Markowitz, Susan Hariri, Eileen F Dunne, et al.
The Journal of Infectious Diseases|May 29, 2016
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness AnalysisJean-François Laprise, Lauri E Markowitz, Harrell W Chesson, et al.
The Journal of Infectious Diseases|February 28, 2002
Persons with early syphilis identified through blood or plasma donation screening in the United StatesCarolyn Gardella, Anthony A Marfin, Richard H Kahn, et al.
Vaccine|October 30, 2020
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission modelHarrell W Chesson, Elissa Meites, Donatus U Ekwueme, et al.
Pageof 29